Figure 1 provides an overview of the meta-analysis of the 4 major datasets. The first is the GWAS of AUD in European Americans (EA) from MVP [6] (herein designated “MVP phase1”), comprised of 202,004 individuals phenotyped for AUD (ncase = 34,658, ncontrol = 167,346, neffective = 114,847) using International Classification of Diseases (ICD) codes [3]. The second, MVP Phase2, included an additional 65,387 EA individuals from MVP (ncase = 11,337, ncontrol = 54,050, neffective = 37,485) not previously analyzed. The third dataset is a GWAS of DSM-IV alcohol dependence (AD) from the Psychiatric Genomics Consortium (PGC), which included 46,568 European participants (ncase = 11,569, ncontrol = 34,999, neffective = 26,853) [2]. The fourth dataset is a GWAS of Alcohol Use Disorders Identification Test–Problems (AUDIT-P; a measure of problematic drinking) scores from a UK Biobank sample (UKB) [7] that included 121,604 European participants [4].
